Remfry & Sagar

MEDIA, ADVERTISING & ENTERTAINMENT Legal Summit, 2024 The #MAELS Annual Summit organised by Lex Witness - India's 1st Magazine on Legal & Corporate Affairs had Remfry & Sagar Partner C.A. Brijesh as a panelist on a discussion titled 'IPR & Content Rights in the M&E sector'. The session was moderated by Lohita Sujith, Sr. Director, Copyright & Digital Economy, Motion Picture Association India and had Himanshu Bagai, Partner, Saikrishna & Associates and Natasha Fernandes, Senior Associate Vice President and Head Legal, IN10 Media Network, as co-panelists. It was an insightful discussion, with Brijesh sharing his views on how #AI will impact #copyright heavy sectors such as #film and #music; ambiguity on #authorship and #ownership related to AI generated works; need to protect #PersonalityRights; as well as cross-border #infringement issues and recommendations - including the role of dynamic injunctions.

AIPPI World Congress 2024: PATENT TERM EXTENSIONS Remfry & Sagar Partner Shukadev Khuraijam was at the 2024 AIPPI World Congress in Hangzhou, China, where he was part of a panel that discussed the impact and relevance of #patent #term #extensions (PTE) in different jurisdictions. The session was titled: 'It's Not Yet My Time: Patent Term Extensions' and involved lively discussions between the panelists - Shukadev as well as Ivy Tsui (Gilead), Lilian Roriz (Licks Attorneys), Hongqiang Liu (Bayer) and Michael Alt (TQJ at the Unified Patent Court). The audience posed quite a few questions and Shukadev explained India’s peculiar position as a developing economy - one which provides over 20% of the world’s supply of generic drugs - and the nuanced balance the Indian government must maintain. He also discussed the proposed FTA agreement between the UK and the Indian government which includes the issue of PTE and hinted that there is more to it than meets the eye! #remfry #patents #AIPPI #AIPPIWorldCongress

Gilead Sciences, a U.S. based #pharmaceutical company, recently signed non-exclusive, royalty-free voluntary #licensing agreements with six #generic manufacturers to produce and sell generic versions of the #HIV prevention drug #Lenacapavir in 120 low- and middle-income countries. Among these countries is India which has the biggest generic drug industry outside the U.S.  Prior to Gilead’s signing of the licensing agreements, #pregrant oppositions to its patent applications in India for Lenacapavir were filed mainly by community health organizations and patient groups. These oppositions are based primarily on the issue of “#evergreening.”  #Lifesciences expert RANJNA MEHTA-DUTT, Partner at Remfry & Sagar, comments on this issue in an article published by Asia IP Magazine which you can read here: https://lnkd.in/dtd4Nx4T

2024 BRICS IP Forum (BIPF) On October 14, 2024 member firms - Daniel Law (Brazil), Gorodissky & Partners (Russia), CCPIT Patent and Trademark Law Office (China), Von Seidels (South Africa) and Remfry & Sagar (India) - met in Seoul, South Korea for the latest edition of the BRICS IP Forum, organised in association with the KOREA PATENT ATTORNEYS ASSOCIATION KPAA. Remfry & Sagar Partner Gaurav Mukerjee's presentation was titled 'Trademark Law in India' while Partner Shukadev Khuraijam spoke on 'Update On Indian Patent Regime: Why Should Applicants File In India?'. The meeting was well attended and the sessions offered valuable takeaways on IP issues both common and peculiar to the 5 BRICS nations. #remfry #thoughleadership #patents #trademarks #BIPF #BRICS #BricsIPForum

Remfry & Sagar: PATENT LITIGATION Firm Of The Year IAM and World Trademark Review (WTR) have announced the winners of the 2024 Global IP Awards. We are delighted to share that Remfry & Sagar has won the award for ‘Patent Litigation Firm Of The Year: India‘. Managing Partner of the Firm, Ashwin Julka, received the award at the ceremony held in London on October 17, 2024. Thank you to our clients and associates for their support - it drives us to continually raise the bar! #remfry #awards #iplitigation #patents #patentlitigation

PATENTS - Section. 3(d) In a case argued by Remfry & Sagar, Nippon Steel v The Controller General of Patents, Designs and Trademarks (2024:DHC:6514), the Delhi High Court has adjudicated on core issues concerning #patent #eligibility assessments of #inventions under Section 3(d) of the Patents Act 1970. Ultimately, the court set aside the Patent Office's refusal order for:  - violating the principles of #naturaljustice;  - lacking technical analysis of the claimed method; - not applying any test or standard for patent eligibility of the subject matter; - for not identifying the known device due to which Section 3(d) was raised and remanded the matter back for fresh consideration. Interestingly, the court has also directed the IPO to delve deeper into other patentability nuances of the invention. RANJNA MEHTA-DUTT and Himani Pandey analyse the significance of this decision in an article published by IAM that you can read here: https://lnkd.in/gbC_X5sT

India's Electric Vehicle Market India is increasingly embracing #electricvehicles, and there is sufficient room for development in several areas to suggest it can join the world’s leading players. In an article published by Managing IP, Sanhita Chatterjee of Remfry & Sagar looks at how technological #innovation fostered by #patent protection is contributing to a changing automotive landscape in the country. Her piece features in the Japanese Buyers' Guide and you can read it here: https://lnkd.in/grcxR7Pz #EV #EVPatents #remfry #GreenIP

Could CLARI-FI Cancel CLARIWASH? L’Oréal requested the cancellation of cosmetic company Innovative Derma Care’s registered #trademark CLARIWASH after the Registrar of Trademarks made an error in the mark’s examination report - search for prior records was conducted re CHARIWASH instead of CLARIWASH and, thus, failed to throw up L'Oreal prior mark CLARI-FI. According to the court, CLARIWASH was not deceptively similar to CLARI-FI, and the former was not liable to be cancelled because the Registrar’s procedural error was not grounds for refusal under trademark law. The CLARIWASH mark was subsequently advertised in the Trademarks Journal, in which it was spelled correctly and though L’Oréal could have reasonably opposed it at that stage, it had failed to do so.  Accordingly, no case for #cancellation was made out. Gaurangi Sharma of Remfry & Sagar analyses this decision in an article published by World Trademark Review, which you can read here: https://lnkd.in/gTFt5jya

Managing IP Awards, 2024 Delighted to share that Remfry & Sagar took home two awards at the recently held Managing IP Awards (Asia-Pacific) Awards in Kuala Lumpur, Malaysia.  Partner Tanmay Joshi was at the awards ceremony to accept the 'THE FIRM OF THE YEAR - TRADEMARKS' award. Also, a patent appeal argued by the Remfry & Sagar team - ISCHEMIX v. CONTROLLER OF PATENTS' was recognised as 'IMPACT CASE OF THE YEAR'.  Thank you to our clients and associates for their trust and support - it drives us to continually raise the bar! #remfry #awards

ANTI-COUNTERFEITING Gaurav Mukerjee, Partner at Remfry & Sagar, was a speaker at the 8th Annual Anti-Counterfeiting and Brand Protection India Summit 2024. He shared his expertise on a panel that discussed the "Legal Challenges in Prosecuting Perpetrators: What Legal Help is Available for Brands? Do’s and Don’ts." The session was moderated by Navin Kumar Singh (General Manager (Legal) at Bharat Petroleum Corporation Limited) and had Abhijit Y. (Legal Director, India Colgate-Palmolive (India)), Prashant Mule (General Manager Anti-counterfeit & Brand Protection, Sintex BAPL Limited (Welspun Group)), Megha Babar (Legal Counsel, India, Syngenta) and Santosh Mane (Head Legal & Compliance, Zydus Wellness) as co-panelists. Critical aspects of brand protection and legal frameworks were discussed and the practical insights were well received by the audience. #anticounterfeiting #remfry #brandprotection